NYSE - Nasdaq Real Time Price USD

Teleflex Incorporated (TFX)

203.01 +4.28 (+2.15%)
At close: May 3 at 4:00 PM EDT
203.01 0.00 (0.00%)
After hours: May 3 at 5:29 PM EDT
Loading Chart for TFX
DELL
  • Previous Close 198.73
  • Open 201.19
  • Bid 81.13 x 1200
  • Ask 202.81 x 800
  • Day's Range 199.12 - 206.51
  • 52 Week Range 177.63 - 262.97
  • Volume 489,174
  • Avg. Volume 302,543
  • Market Cap (intraday) 9.562B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 32.48
  • EPS (TTM) 6.25
  • Earnings Date Aug 1, 2024 - Aug 5, 2024
  • Forward Dividend & Yield 1.36 (0.67%)
  • Ex-Dividend Date Feb 29, 2024
  • 1y Target Est 254.92

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

www.teleflex.com

14,500

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TFX

Performance Overview: TFX

Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TFX
18.46%
S&P 500
7.50%

1-Year Return

TFX
23.99%
S&P 500
24.47%

3-Year Return

TFX
51.20%
S&P 500
22.64%

5-Year Return

TFX
30.28%
S&P 500
75.76%

Compare To: TFX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TFX

Valuation Measures

Annual
As of 5/3/2024
  • Market Cap

    9.56B

  • Enterprise Value

    11.19B

  • Trailing P/E

    32.43

  • Forward P/E

    14.88

  • PEG Ratio (5yr expected)

    2.35

  • Price/Sales (ttm)

    3.20

  • Price/Book (mrq)

    2.12

  • Enterprise Value/Revenue

    3.73

  • Enterprise Value/EBITDA

    17.25

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.82%

  • Return on Assets (ttm)

    3.32%

  • Return on Equity (ttm)

    6.87%

  • Revenue (ttm)

    3B

  • Net Income Avi to Common (ttm)

    296.02M

  • Diluted EPS (ttm)

    6.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    237.42M

  • Total Debt/Equity (mrq)

    41.37%

  • Levered Free Cash Flow (ttm)

    265.59M

Research Analysis: TFX

Company Insights: TFX

Research Reports: TFX

People Also Watch